49 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
6
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Merck Research Laboratories
4
Serendipitous oxidation product of BIBN4096BS: a potent CGRP receptor antagonist.
Bristol Myers Squibb
50
Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
Vertex Pharmaceuticals
24
Preparation of imidazoles as potent calcitonin gene-related peptide (CGRP) antagonists.
Bristol Myers Squibb
15
[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
Merck Research Labortories
5
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery.
Bristol Myers Squibb
16
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.
Bristol Myers Squibb
30
Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.
Glaxosmithkline
5
Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine.
Bristol Myers Squibb
4
Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine.
TBA
16
Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor.
Bristol Myers Squibb
26
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
Bristol Myers Squibb
8
MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
Merck Research Laboratories
45
Calcitonin gene-related peptide (CGRP) receptor antagonists: pyridine as a replacement for a core amide group.
Bristol Myers Squibb
39
Calcitonin gene-related peptide (CGRP) receptor antagonists: novel aspartates and succinates.
Bristol Myers Squibb
32
Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template.
Merck Research Laboratories
30
Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Merck Research Laboratories
12
Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.
Merck
21
Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.
Merck Research Laboratories
18
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.
Merck
10
The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
Merck Research Laboratories
13
Quinine analogs as non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists
TBA
13
Carbamates as potent calcitonin gene-related peptide antagonists with improved solution stability.
Bristol Myers Squibb
4
Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and effic
Bristol Myers Squibb
30
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974).
Merck Research Laboratories
15
Macrocyclization strategy for improving candidate profiles in medicinal chemistry.
Gachon University
2
Resveratrol derivatives: Synthesis and their biological activities.
Universitat De Barcelona
10
Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor.
Université
20
Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.
Merck Research Laboratories
50
Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine.
Merck Research Laboratories
20
Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist
Boehringer Ingelheim Pharma
16
Calcitonin gene-related peptide (CGRP) receptor antagonists: Heterocyclic modification of a novel azepinone lead.
Bristol Myers Squibb
23
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists.
Bristol Myers Squibb
63
From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor.
Eth ZüRich
9
Structure-activity study of hCGRP8-37, a calcitonin gene-related peptide receptor antagonist.
Université
292
Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
Merck Sharp & Dohme
3
Inhibitors of protein tyrosine phosphatases
Indiana University Research and Technology
5
Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Harvard Medical School